Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Comparison of efficacy and safety profiles of rivaroxaban and aspirin versus clopidogrel and aspirin in the prevention of atherosclerotic events in Chinese dyslipidemic patients with coronary artery disease

Rongzu Tu¹ , Zhaie Lu²

¹Department of Internal Medicine, Ningbo Women and Children's Hospital, Ningbo, Zhejiang 315000, China; ²Department of Obstetrics and Gynecology, Ningbo Women and Children's Hospital, Ningbo, Zhejiang 315000, China.

For correspondence:- Rongzu Tu Email: rongzu_tu231@hotmail.com Tel:+8613532233241

Accepted: 27 September 2022 Published: 28 October 2022

Citation: Tu R, Lu Z. Comparison of efficacy and safety profiles of rivaroxaban and aspirin versus clopidogrel and aspirin in the prevention of atherosclerotic events in Chinese dyslipidemic patients with coronary artery disease. Trop J Pharm Res 2022; 21(10):2247-2251 doi: 10.4314/tjpr.v21i10.28

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To compare the efficacy and safety profiles of rivaroxaban (R) + aspirin (A) and clopidogrel (C) + aspirin (A) in the prevention of atherosclerotic events in Chinese dyslipidemic patients with coronary artery disease (CAD).

Methods: Coronary artery disease patients were given either R (10 mg daily) + A (100 mg daily) or C (75 mg daily) plus A (100 mg daily), with 105 subjects in each group. Each patient was followed up for 30 months. The following clinical outcomes (as aspects of primary endpoints) were assessed: percentge of patients with incidence of atherosclerotic events, and deaths due to any cause/cardiovascular causes. Hazard ratios and safety were also determined.

Results: A total of 210 enrolled patients completed the study. Compared to C + A group, patients treated with R + A had slightly lower incidence of atherosclerotic events (33.2 vs 32.6 %, p > 0.05) and lower death rate due to any cause/cardiovascular causes (3.1 vs 2 %, p > 0.05). Patients treated with R + A had significantly greater incidence of bleeding (p < 0.05).

Conclusion: The R + A treatment is more effective than C + A treatment in the prevention of atherosclerotic events, although this was not statistically significant different. The incidence of bleeding are significantly higher in R + A group than in C + A group.

Keywords: Aspirin, Clopidogrel, Rivaroxaban, Coronary artery disease, Atherosclerotic, Dyslipidaemia